April 2005 in “The Journal of urology/The journal of urology” Dutasteride may help treat prostate cancer by causing cancer cells to shrink and die.
116 citations,
May 1992 in “The American Journal of Medicine” Flutamide rarely causes liver toxicity in prostate cancer patients.
1 citations,
May 2001 in “Journal of Labelled Compounds and Radiopharmaceuticals” Scientists at the University of Michigan Medical School successfully created a special compound that can be used to improve imaging of prostate cancer.
10 citations,
October 2012 in “Andrology” Prostate cancer can progress even with low testosterone due to internal hormone production in the tumor.
9 citations,
June 2018 in “Scientific Reports” People with certain types of alopecia have a slightly higher risk of cancer, especially thyroid, bladder, and prostate cancers.
February 2017 in “Cancer Causes & Control” Swedish men with the E213 A-allele of the androgen receptor have a lower risk of prostate cancer.
April 2012 in “The Journal of Urology” Eating more omega-3 and less omega-6 fatty acids may lower the risk of developing prostate cancer.
2 citations,
January 2011 in “Clinical medicine insights” Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.
April 2022 in “Diabetes Therapy” Low testosterone does not prevent prostate cancer in men with type 1 diabetes.
54 citations,
November 2001 in “Urology” The length of the CAG repeat in the androgen receptor gene affects the risk and progression of prostate cancer, BPH, infertility, and undermasculinized genitalia.
33 citations,
January 2016 in “Indian Journal of Dermatology, Venereology and Leprology” Taking 1 mg of finasteride daily can increase hair count and improve hair appearance, but it may have side effects on sexual function and a potential risk of prostate cancer. It may not be effective for postmenopausal women unless taken in higher doses.
7 citations,
August 2006 in “Maturitas” Cimicifuga racemosa extract may help prevent and treat prostate issues by inhibiting 5α-reductase.
224 citations,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
April 2022 in “Authorea (Authorea)” CT scans can find serious prostate cancer even when PSA levels are low.
16 citations,
October 1994 in “The Journal of Steroid Biochemistry and Molecular Biology” Two non-steroidal antiandrogens, RU 58841 and RU 56187, form a common metabolite at different rates, which may influence their effects; RU 56187 could be used for prostate cancer treatment and RU 58841 for acne treatment.
9 citations,
September 2014 in “Cancer Epidemiology, Biomarkers & Prevention” Certain genetic variants in the androgen receptor are linked to higher PSA levels, potentially affecting prostate cancer screening outcomes.
21 citations,
June 2002 in “PubMed” The conclusion is that there might be a link between certain types of baldness and prostate cancer, which could be due to shared hormonal pathways.
September 2010 in “European Urology Supplements” Serum triglyceride levels are not linked to prostate cancer risk.
September 2010 in “European Urology Supplements” The document does not confirm if radical prostatectomy is the best treatment for locally advanced prostate cancer.
45 citations,
January 2020 in “International Journal of Molecular Sciences” Some natural compounds may help overcome drug resistance in certain cancers, but more research is needed.
13 citations,
May 2018 in “Urologic Oncology: Seminars and Original Investigations” Finasteride does not prevent bladder cancer.
2 citations,
April 2021 in “Canadian Journal of Urology” Five-alpha reductase inhibitors, like finasteride and dutasteride, can treat enlarged prostates, improve urination, reduce need for prostate surgery, and lower the risk of prostate cancer, but may increase the risk of higher grade prostate cancer. They can also treat male pattern baldness.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.
1 citations,
April 2019 in “Clinical Breast Cancer” Medicines for enlarged prostate may raise the risk of breast growth and tenderness but not breast cancer.
6 citations,
September 1997 in “Prostate Cancer and Prostatic Diseases” Finasteride 5 mg effectively reduces urinary symptoms and PSA levels in men with enlarged prostates, with few sexual side effects.
November 2013 in “International Journal of Dermatology” New skin lesions on the scrotum or vulva in patients with a history of internal cancer could indicate rare skin metastasis.
29 citations,
March 2010 in “Cancer epidemiology” Men who start losing hair at age 30 may have a lower risk of prostate cancer.
November 2023 in “Bioorganic Chemistry” Drugs targeting the Androgen Receptor are effective for treating prostate cancer and other androgen-related conditions.
89 citations,
December 2006 in “Lancet Oncology” Taking 1 mg/day finasteride for hair loss significantly lowers PSA levels in men, which may affect prostate cancer screening.